RU2002123182A - Содержащая ибупрофен композиция - Google Patents
Содержащая ибупрофен композицияInfo
- Publication number
- RU2002123182A RU2002123182A RU2002123182/15A RU2002123182A RU2002123182A RU 2002123182 A RU2002123182 A RU 2002123182A RU 2002123182/15 A RU2002123182/15 A RU 2002123182/15A RU 2002123182 A RU2002123182 A RU 2002123182A RU 2002123182 A RU2002123182 A RU 2002123182A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- solid dosage
- ibuprofen
- drug
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Способ получения композиции, содержащей ибупрофен, отличающийся тем, что ибупрофен или его соли покрывают гидроксиметилпропилцеллюлозой, метилцеллюлозой, натрийкарбоксиметилцеллюлозой или желатиной, причем в пересчете на сухой вес композиции доля связующего составляет от 0,1 до 10 мас.% и доля ибупрофена или его солей составляет от 90 до 99,9 мас.%.
2. Способ по п.1, отличающийся тем, что к подлежащему покрытию ибупрофену или его солям добавляют от 0,1 до 1,5 мас.% высокодисперсного диоксида кремния, в пересчете на сухой вес композиции.
3. Композиция, получаемая согласно способу по п.1 или 2.
4. Композиция, включающая от 90,0 до 99,9 мас.% ибупрофена или его солей, от 0,1 до 10,0 мас.% гидроксипропилметилцеллюлозы, метилцеллюлозы, натрийкарбоксиметилцеллюлозы, гидроксипропилцеллюлозы или желатины в качестве связующего и от 0,1 bis 1,5 мас.% высокодисперсного диоксида кремния, в пересчете на сухой вес композиции, причем полученные из этой композиции при усилии прессования от 4,7 до 5,3 кн пресс-изделия с содержанием ибупрофена в 200 мг и диаметром в 9 мм имеют твердость по меньшей мере 25 н.
5. Применение композиции по п.3 или 4 для получения лекарственных препаратов или твердых лекарственных форм.
6. Лекарственный препарат, содержащий композицию по п.3 или 4.
7. Лекарственный препарат по п.6, отличающийся тем, что лекарственный препарат содержит дополнительно к композиции вспомогательные вещества для таблеток.
8. Лекарственный препарат по п.7, отличающийся тем, что в качестве вспомогательных веществ для таблеток содержатся вещества, которые замедляют высвобождение активного вещества из твердой лекарственной формы.
9. Лекарственный препарат по одному из пп.6 - 8, содержащий дополнительно другие активные вещества.
10. Применение лекарственных препаратов по одному из пп.6 - 9 для получения твердых лекарственных форм.
11. Способ получения твердых лекарственных форм, отличающийся тем, что композицию по п.3 или 4 или лекарственный препарат по одному из пп.6 - 9 прессуют в твердую форму и, в случае необходимости, покрывают эту твердую лекарственную форму покрывающим веществом.
12. Твердая лекарственная форма, содержащая композицию по п.3 или 4.
13. Твердая лекарственная форма, содержащая лекарственный препарат по пп.6 - 9.
14. Твердая лекарственная форма по п.12 или 13 с содержанием ибупрофена более 75 мас.%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003757.7 | 2000-01-28 | ||
| DE10003757A DE10003757A1 (de) | 2000-01-28 | 2000-01-28 | Ibuprofen-Wirkstoffzubereitung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002123182A true RU2002123182A (ru) | 2004-03-20 |
| RU2300368C2 RU2300368C2 (ru) | 2007-06-10 |
Family
ID=7629069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002123182/15A RU2300368C2 (ru) | 2000-01-28 | 2001-01-19 | Содержащая ибупрофен композиция |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20030045580A1 (ru) |
| EP (1) | EP1250132B1 (ru) |
| JP (1) | JP2003525223A (ru) |
| KR (1) | KR100742489B1 (ru) |
| CN (1) | CN1277535C (ru) |
| AT (1) | ATE291908T1 (ru) |
| AU (1) | AU784128B2 (ru) |
| BR (1) | BR0107899A (ru) |
| CA (1) | CA2398288A1 (ru) |
| CZ (1) | CZ296485B6 (ru) |
| DE (2) | DE10003757A1 (ru) |
| ES (1) | ES2239119T3 (ru) |
| HU (1) | HUP0204202A3 (ru) |
| IL (2) | IL150528A0 (ru) |
| MX (1) | MXPA02007076A (ru) |
| NO (1) | NO20023551L (ru) |
| RU (1) | RU2300368C2 (ru) |
| TW (1) | TWI288641B (ru) |
| WO (1) | WO2001054683A1 (ru) |
| ZA (1) | ZA200206833B (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2478375C2 (ru) * | 2007-03-13 | 2013-04-10 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Распадающаяся во рту таблетка |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0209265D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| JP5248733B2 (ja) * | 2003-11-28 | 2013-07-31 | エスエス製薬株式会社 | 揮散防止型固形製剤およびその製造方法 |
| US20070077297A1 (en) | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
| US20060068009A1 (en) * | 2004-09-30 | 2006-03-30 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
| BRPI0503756A (pt) * | 2005-09-06 | 2007-05-15 | Gold Nutrition Pesquisa Desenv | método de processamento de soja pelo uso de enzima especìfica, pó de soja processada e lìquido de soja processada |
| ES2380747T3 (es) | 2006-07-18 | 2012-05-18 | Horizon Pharma Usa, Inc. | Métodos y medicamentos para administración de ibuprofeno |
| US7749537B2 (en) * | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
| CN101829064B (zh) * | 2010-04-27 | 2012-04-25 | 海南新中正制药有限公司 | 右旋布洛芬颗粒及其制备方法 |
| JP5840201B2 (ja) | 2010-05-10 | 2016-01-06 | ユーロ−セルティーク エス．エイ． | 活性剤を負荷した顆粒と追加の活性剤の組合せ |
| NZ603173A (en) | 2010-05-10 | 2014-10-31 | Euro Celtique Sa | Manufacturing of active-free granules and tablets comprising the same |
| JP2010189443A (ja) * | 2010-06-07 | 2010-09-02 | Ss Pharmaceut Co Ltd | 揮散防止型固形製剤およびその製造方法 |
| CN102988322B (zh) * | 2012-12-26 | 2014-09-03 | 合肥科大生物技术有限公司 | 一种精氨酸布洛芬片剂及其制备方法 |
| US9615595B2 (en) | 2013-03-05 | 2017-04-11 | Mera Technology International Inc. | Method and apparatus for wasteless homogenized soybean beverage production |
| DE112014005175T5 (de) | 2013-11-13 | 2016-07-21 | Euro-Celtique S.A. | Hydromorphon und Naloxon für die Behandlung von Schmerzen und Opioid-Darm-Dysfunktions-Syndrom |
| US11510877B2 (en) | 2017-10-10 | 2022-11-29 | Capsugel Belgium Nv | Gelling multiparticulates |
| BR112021016485A2 (pt) | 2019-02-22 | 2021-10-13 | Catalent U.K. Swindon Zydis Limited | Minimização de aglomeração de material de revestimento de partícula de fármaco durante armazenamento para estabilizar tempos de desintegração de produtos farmacêuticos |
| GB2597578B (en) | 2019-02-22 | 2023-04-26 | Catalent Uk Swindon Zydis Ltd | Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension |
| BR112021016421A2 (pt) * | 2019-02-22 | 2021-10-13 | Catalent U.K. Swindon Zydis Limited | Minimização de aglomeração, aeração e preservação do revestimento de composições farmacêuticas que compreendem ibuprofeno |
| JP7681511B2 (ja) | 2019-02-22 | 2025-05-22 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | インライン混合中の懸濁液の通気の最小化 |
| AR123109A1 (es) * | 2020-07-31 | 2022-10-26 | Catalent Uk Swindon Zydis Ltd | Composiciones farmacéuticas que comprenden ifa |
| US20220312830A1 (en) * | 2021-04-06 | 2022-10-06 | Altria Client Services Llc | Nicotine-containing agglomerates and methods of forming the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
| US4980375A (en) * | 1987-07-10 | 1990-12-25 | Sterling Drug Inc. | Onset-hastened/enhanced antipyretic response |
| US4911921A (en) * | 1989-02-02 | 1990-03-27 | Mallinckrodt, Inc. | High ibuprofen content granulations |
| US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| HUT59653A (en) * | 1990-11-15 | 1992-06-29 | Puetter Medice Chem Pharm | Process for producing complexes containing s/+/-phenyl-alcanoic acids and alpha-hydroxy-alcanoic acids and pharmaceutical compositions containing them as active components |
| GB9119052D0 (en) * | 1991-09-06 | 1991-10-23 | Boots Co Plc | Pharmaceutical compositions |
| US5191114A (en) * | 1991-10-09 | 1993-03-02 | Sage Pharmaceuticals, Inc. | Process for enhancing the flow characteristics of ibuprofen |
| US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
| IT1270239B (it) * | 1994-06-17 | 1997-04-29 | Zambon Spa | Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo |
| PL181215B1 (pl) * | 1994-08-23 | 2001-06-29 | Smithkline Beecham Plc | Kompozycja farmaceutyczna zawierająca ibuprofen i kodeinę oraz sposób jej wytwarzania |
| US5534263A (en) * | 1995-02-24 | 1996-07-09 | Alza Corporation | Active agent dosage form comprising a matrix and at least two insoluble bands |
| US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| US5780055A (en) * | 1996-09-06 | 1998-07-14 | University Of Maryland, Baltimore | Cushioning beads and tablet comprising the same capable of forming a suspension |
| US5904937A (en) * | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
-
2000
- 2000-01-28 DE DE10003757A patent/DE10003757A1/de not_active Withdrawn
-
2001
- 2001-01-09 TW TW090100451A patent/TWI288641B/zh not_active IP Right Cessation
- 2001-01-19 KR KR1020027009476A patent/KR100742489B1/ko not_active Expired - Fee Related
- 2001-01-19 RU RU2002123182/15A patent/RU2300368C2/ru not_active IP Right Cessation
- 2001-01-19 WO PCT/EP2001/000602 patent/WO2001054683A1/de not_active Ceased
- 2001-01-19 CZ CZ20022605A patent/CZ296485B6/cs not_active IP Right Cessation
- 2001-01-19 CA CA002398288A patent/CA2398288A1/en not_active Abandoned
- 2001-01-19 US US10/181,459 patent/US20030045580A1/en not_active Abandoned
- 2001-01-19 CN CNB018042325A patent/CN1277535C/zh not_active Expired - Fee Related
- 2001-01-19 HU HU0204202A patent/HUP0204202A3/hu unknown
- 2001-01-19 AT AT01902340T patent/ATE291908T1/de not_active IP Right Cessation
- 2001-01-19 AU AU30197/01A patent/AU784128B2/en not_active Ceased
- 2001-01-19 ES ES01902340T patent/ES2239119T3/es not_active Expired - Lifetime
- 2001-01-19 DE DE50105771T patent/DE50105771D1/de not_active Expired - Fee Related
- 2001-01-19 MX MXPA02007076A patent/MXPA02007076A/es active IP Right Grant
- 2001-01-19 JP JP2001555661A patent/JP2003525223A/ja not_active Withdrawn
- 2001-01-19 EP EP01902340A patent/EP1250132B1/de not_active Expired - Lifetime
- 2001-01-19 BR BR0107899-2A patent/BR0107899A/pt not_active Application Discontinuation
- 2001-01-19 IL IL15052801A patent/IL150528A0/xx active IP Right Grant
-
2002
- 2002-07-02 IL IL150528A patent/IL150528A/en not_active IP Right Cessation
- 2002-07-25 NO NO20023551A patent/NO20023551L/no not_active Application Discontinuation
- 2002-08-27 ZA ZA200206833A patent/ZA200206833B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2478375C2 (ru) * | 2007-03-13 | 2013-04-10 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Распадающаяся во рту таблетка |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003525223A (ja) | 2003-08-26 |
| KR20020069368A (ko) | 2002-08-30 |
| ZA200206833B (en) | 2003-08-27 |
| CN1400896A (zh) | 2003-03-05 |
| MXPA02007076A (es) | 2003-03-27 |
| DE50105771D1 (de) | 2005-05-04 |
| ATE291908T1 (de) | 2005-04-15 |
| CA2398288A1 (en) | 2001-08-02 |
| AU3019701A (en) | 2001-08-07 |
| RU2300368C2 (ru) | 2007-06-10 |
| NO20023551D0 (no) | 2002-07-25 |
| HUP0204202A2 (hu) | 2003-03-28 |
| DE10003757A1 (de) | 2001-08-02 |
| ES2239119T3 (es) | 2005-09-16 |
| CZ296485B6 (cs) | 2006-03-15 |
| CN1277535C (zh) | 2006-10-04 |
| IL150528A0 (en) | 2003-02-12 |
| HUP0204202A3 (en) | 2003-04-28 |
| NO20023551L (no) | 2002-07-25 |
| KR100742489B1 (ko) | 2007-07-24 |
| AU784128B2 (en) | 2006-02-09 |
| EP1250132B1 (de) | 2005-03-30 |
| BR0107899A (pt) | 2002-11-05 |
| IL150528A (en) | 2007-06-17 |
| CZ20022605A3 (cs) | 2003-02-12 |
| TWI288641B (en) | 2007-10-21 |
| US20030045580A1 (en) | 2003-03-06 |
| WO2001054683A1 (de) | 2001-08-02 |
| EP1250132A1 (de) | 2002-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002123182A (ru) | Содержащая ибупрофен композиция | |
| EA200600884A1 (ru) | Композиции комплексов экстроген-циклодекстрин | |
| UA41346C2 (ru) | Фармацевтическая композиция, содержащая флуоксетин или его соль, таблетка на ее основе, способ производства диспергируемых таблеток | |
| DE69927963D1 (de) | Gelierbare pharmazeutische zusammensetzungen | |
| ATE100708T1 (de) | Unbeschichtete pharmazeutische reaktionstablette. | |
| ATE206304T1 (de) | Bioadhesive feste arzneimittelform | |
| DE60129573D1 (de) | Verfahren zur sprühtrocknung von zusammensetzungen enthaltend fenofibrat | |
| ZA992951B (en) | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. | |
| RU2000100756A (ru) | Способы и составы для модулирования сексуальной реакции человека | |
| NZ507566A (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
| MY129234A (en) | Oral pharmaceutical forms of administration with a delayed action with tramadol. | |
| KR890001526A (ko) | 경구용 서방성 아세트 아미노펜 제형 및 이의 제조방법 | |
| TNSN03106A1 (fr) | Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuse uniforme | |
| KR850700212A (ko) | 서방성 약제학적 캼셀제 | |
| AU2793989A (en) | Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained | |
| ES2029228T3 (es) | Procedimiento para la produccion de un preparado retardado de ibuprofeno. | |
| KR900004326A (ko) | 디히드로에르고톡신 및 그의 산 부가염의 분산성 정제 | |
| KR910011241A (ko) | 정제로 직접 압착 가능한 약제학적 분말 조성물을 제조하기 위한 분무 건조법 | |
| SE8901003L (sv) | Snabbloesliga preparat | |
| GR20010100377A (el) | Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη | |
| WO2003028624A3 (en) | Levothyroxine compositions and methods | |
| KR950703518A (ko) | 틸리딘 이수소 오르토포스페이트, 그 제조방법 및 이를 함유한 의약 제제(tilidin dihydrogen orthophosphate, method of preparing it and pharmaceutical preparations containingit) | |
| DK162017B (da) | Farmaceutisk tablet med kontrolleret frigivelse og fremgangsmaade til dens fremstilling | |
| KR960700701A (ko) | 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof) | |
| WO2003013441A3 (en) | Levothyroxine compositions and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100120 |